15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.8B | -$1.1B | 46.7% | 1.0% | -$293M | — | $282M |
| 2024 | $2.7B | -$363M | 82.8% | -8.1% | -$9M | — | $28M |
| 2023 | $2.6B | -$41M | 83.3% | 5.2% | $568M | — | $243M |
| 2022 | $10.0B | $22M | 18.3% | 1.4% | — | — | $69M |
| 2021 | $9.8B | $222M | 15.5% | 3.8% | — | — | $56M |
| 2020 | $8.5B | $30M | 15.1% | 2.4% | — | $1.0B | $83M |
| 2019 | $9.2B | -$62M | 12.3% | 0.8% | — | $1.6B | $67M |
| 2018 | $9.4B | -$437M | 11.4% | -3.7% | — | $1.7B | $66M |
| 2017 | $9.3B | $73M | 12.6% | 1.0% | — | $917M | $105M |
| 2016 | $9.7B | $109M | 12.2% | 2.1% | — | $569M | $185M |
| 2015 | — | $103M | — | — | — | $578M | $161M |
| 2014 | — | $67M | — | — | -$52M | $614M | $57M |
| 2013 | — | $111M | — | — | $112M | $216M | $102M |
| 2012 | — | $109M | — | — | $209M | $218M | $98M |
| 2011 | — | $115M | — | — | $43M | $215M | $136M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $628M | -$6M | 44.3% | 2.7% | -$92M | — | $337M |
| Dec '25 | $709M | -$56M | 45.6% | 2.9% | — | — | $282M |
| Sep '25 | $697M | -$150M | 46.2% | 3.8% | — | — | $33M |
| Jun '25 | $682M | -$869M | 47.6% | -5.8% | — | — | $38M |
| Mar '25 | $674M | -$25M | 78.1% | 2.9% | -$81M | — | $59M |
| Dec '24 | $695M | -$296M | 83.4% | -39.2% | — | — | $28M |
| Sep '24 | $687M | -$13M | 81.5% | 4.5% | — | — | $45M |
| Jun '24 | $660M | -$32M | 82.4% | 2.6% | — | — | $244M |
| Mar '24 | $2.6B | -$22M | 20.5% | 0.4% | — | — | $245M |
| Dec '23 | $2.7B | $18M | 21.5% | 2.3% | — | — | $243M |
| Sep '23 | $2.6B | -$6M | 20.8% | 0.9% | — | — | $215M |
| Jun '23 | $2.6B | -$28M | 20.3% | 0.4% | — | — | $286M |
| Mar '23 | $2.5B | -$24M | 19.7% | 0.4% | — | — | $67M |
| Dec '22 | $2.6B | -$58M | 16.0% | -2.1% | — | — | $69M |
| Sep '22 | $2.5B | $12M | 20.6% | 2.4% | — | — | $77M |
| Jun '22 | $2.5B | $29M | 21.3% | 3.0% | — | — | $56M |
| Mar '22 | $2.4B | $39M | 15.5% | 2.5% | — | — | $211M |
| Dec '21 | $2.5B | $42M | 13.8% | 2.5% | — | — | $56M |
| Sep '21 | $2.5B | $44M | 13.1% | 2.5% | — | — | $40M |
| Jun '21 | $2.5B | $66M | 16.1% | 3.9% | — | — | $45M |
How the market has priced ACH against its own fundamentals since 2026-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, ACCENDRA HEALTH INC/VA/'s revenue has declined 20.1% per year. These are computed facts, not advice.
As of FY2025, ACCENDRA HEALTH INC/VA/ reported — of total debt against $282M of cash; operating income covered interest expense 0.3×.
In FY2025, gross margin was 46.7%, operating margin 1.0%, and net margin -39.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.